Search

Displaying results 7691 - 7700 of 10000 in total
  1. Drug

    Cyprenorphine

    go.drugbank.com/drugs/DB01480
    ExperimentalIllicit

    Categories: Heterocyclic Compounds with 4 or More Rings
  2. Drug

    Coproporphyrinogen III

    go.drugbank.com/drugs/DB04461
    Experimental

    Categories: Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Dimetotiazine

    go.drugbank.com/drugs/DB08967
    Approved

    Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.

  4. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination … With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)).

  5. Drug

    Imdatifan

    go.drugbank.com/drugs/DB21643
    Experimental

    Imdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor. … Imdatifan has a monoisotopic molecular weight of 385.05 Da.

  6. Drug

    Phenibut

    go.drugbank.com/drugs/DB13455
    Experimental

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  7. Drug

    4-Methoxyamphetamine

    go.drugbank.com/drugs/DB01472
    ExperimentalIllicit

    Synonyms: D,L-p-methoxyamphetamineCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  8. Drug

    DA-8031

    go.drugbank.com/drugs/DB19024
    Investigational

    DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).

  9. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  10. Drug

    Camrelizumab

    go.drugbank.com/drugs/DB14776
    Investigational

    Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).